Charcot-Marie-Tooth disease (CMT) is a group of inherited neurological disorders that cause damage to the peripheral nerves. CMT affects the peripheral nervous system, which transmits signals between the central nervous system (brain and spinal cord) and all other parts of the body. The major symptoms of CMT include weakness and wasting away of muscles in the lower legs and feet. Current treatment options for CMT are limited and focus on managing symptoms, with no cure available.
The global Charcot-Marie-Tooth Disease Market is estimated to be valued at US$ 1208.92 Mn in 2023 and is expected to exhibit a CAGR of 23% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity
There is significant growth opportunity for drugs that can effectively treat the underlying cause and slow the progression of CMT. Currently there is no approved drug that directly targets the genetic causes or pathophysiology of CMT. Several pharmaceutical companies are actively conducting clinical trials to develop treatments such as gene therapies, neurotrophic factors, neuroprotective agents, and antisense oligonucleotides that can potentially slow nerve damage or regeneration in CMT. A successful drug therapy that received regulatory approval will capture a large share of the CMT treatment market and substantially increase the market size over the forecast period.
Porter's Analysis
Threat of new entrants: Low due to high R&D cost required for drug development. Also, presence of key players have strong distribution channels and customer loyalty.
Bargaining power of buyers: Moderate as very few treatment options are available. However, growing awareness is reducing buyer dependency on existing brands.
Bargaining power of suppliers: Moderate due to availability of alternative suppliers. However, regulations and expertise required gives existing suppliers an advantage.
Threat of new substitutes: Low as CMT disease has limited treatment options currently. New substitutes will require significant investment and time for development and approval.
Competitive rivalry: High owing to presence of major multinational players investing in R&D to develop novel therapies.
SWOT Analysis
Strength: Growing research focus on identifying drug targets and biomarkers. Rising healthcare expenditure in developed nations.
Weakness: Lack of approved drugs. High cost of R&D due to complexity of disease. Challenges in clinical trial designs.
Opportunity: Emerging novel drug delivery systems. Expanding patient population in developing countries.
Threats: Stringent regulatory norms. Risk of clinical trial failure. Competition from other therapeutic areas.
Key Takeaways
The Global Charcot-Marie-Tooth Disease Market Size is expected to witness high growth led by the United States. The US contributes over 35% share owing to structured healthcare industry and presence of regional leaders.
Europe is the second largest market growing at a CAGR above 20% during the forecast period. This is attributable to large patient population and increasing government support for orphan disease research.
Key players operating in the Charcot-Marie-Tooth Disease market are Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. Regional analysis Neurogene Inc, based out of US, has several clinical candidates targeting CMT1A and CMT1X genetically confirmed forms of CMT. Genzyme Corp offers treatment for symptomatic relief through physical and occupational therapy for patients.
Get More Insights On This Topic: https://www.newswirestats.com/charcot-marie-tooth-disease-market-forecast-outlook-trend-2023-2030/
Sign in to leave a comment.